Serum levels of macrophage migration inhibitory factor in patients with breast cancer and its clinical significance

doi:10.3877/cma.j.issn.1674-0793.2011.02.013

Abstract

Abstract:

Objective

To study the relationship between serum macrophage migration inhibitory factor (MIF) levels and clinical features in the patients with breast cancer.

Methods

Enzyme-linked immunosorbent assay was used to detect the concentration of MIF, IL-8 and VEGF in sera of 54 patients with breast cancer and 46 healthy controls from October 2006 to March 2007.The relationship between serum MIF, IL-8 and VEGF levels and clinical features was analyzed.

Results

The levels of MIF, IL-8 and VEGF in the sera of patients with breast cancer were significantly increased compared to healthy controls(P<0.05). The levels of MIF in breast cancer were significantly correlated with clinical progression pathology stages(P<0.05) and lymph node metastasis(P<0.05). Serum MIF levels correlated positively with serum IL-8 levels (r=0.612, P<0.01).

Conclusion

MIF may be involved in the progression of breast cancer and serum MIF may be a useful biological marker of tumor invasiveness for patients with breast cancer.

Key words: Breast cancer, MIFL VEGF, IL-8

Xiang-dong XU, Bo WANG, Chen YAO, Ying LIN, Shen-ming WANG. Serum levels of macrophage migration inhibitory factor in patients with breast cancer and its clinical significance[J]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(02): 140-143.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2011.02.013

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2011/V05/I02/140

Figures/Tables 2

References 13

1	Agarwal R, Whang DH, Alvero AB, et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol, 2007, 196(4): 348.e1-5.
2	Suzuki F, Nakamaru Y, Oridate N, et al. Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Oncol Rep, 2005, 13(1): 59-64.
3	Hira E, Ono T, Dhar DK, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer, 2005, 103(3): 588-598.
4	He XX, Yang J, Ding YW, et al. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut, 2006, 55(6): 797-802.
5	Ren Y, Chan HM, Fan J, et al. Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene, 2006, 25: 3501-3508.
6	徐向东, 姚陈, 林颖, 等. 乳腺癌组织中巨噬细胞移动抑制因子表达与预后的关系. 中华外科杂志, 2008, 88(8): 520-523.
7	Bando H, Matsumoto G, Bando M, et al. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res, 2002, 93(4): 389-396.
8	王东, 刘敏, 李雯, 等. 原发性肝细胞癌患者血清巨噬细胞移动抑制因子水平与血管内皮生长因子和临床病理的关系. 中华检验医学杂志, 2009, 32(9): 1011-1014.
9	Benoy IH, Salgado R, Van Dam P, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res, 2004, 10(21): 7157-7162.
10	Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol, 2001, 19(4): 1207-1225.
11	XD Xu, Bo Wang, Cai Sheng Ye, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer letters, 2008, 261(2): 147-157.
12	Ren Y, Law S, Huang X, et al. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg, 2005, 242(1): 55-63.
13	White ES, Flaherty KR, Carskadon S, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res, 2003, 9(2): 853-860.

组别	例数	MIF(ng/ml)	VEGF(pg/ml)	IL-8(pg/ml)
乳腺癌组	54	91.1±43.2	318.7±83.1	12.3±7.7
健康对照组	46	8.3±3.9	151.9±36.0	5.0±1.3

组别	例数	MIF(ng/ml)	VEGF(pg/ml)	IL-8(pg/ml)
乳腺癌组	54	91.1±43.2	318.7±83.1	12.3±7.7
健康对照组	46	8.3±3.9	151.9±36.0	5.0±1.3

临床病理特征		例数	MIF表达血清(ng/ml)	P值
年龄（岁）		?	?	?
?	≤50	30	82.5±37.8	0.141
?	>50	24	101.9±47.0	?
病理类型		?	?	?
?	浸润性癌	42	95.7±45.2	0.150
?	非浸润性癌	12	75.3±32.2	?
肿瘤分期		?	?	?
?	Ⅰ/Ⅱ	41	86.7±37.8	0.022
?	Ⅲ	13	101.0±53.1	?
淋巴结转移		?	?	?
?	阴性	28	79.1±31.1	0.035
?	阳性	26	104.2±50.7	?
雌激素受体		?	?	?
?	阳性	29	87.8±41.8	0.574
?	阴性	25	95.0±45.3	?
孕激素受体		?	?	?
?	阳性	26	93.1±41.0	0.751
?	阴性	28	89.3±45.9	?
HER2		?	?	?
?	阳性	19	102.9±42.8	0.146
?	阴性	35	84.8±45.9	?

临床病理特征		例数	MIF表达血清(ng/ml)	P值
年龄（岁）		?	?	?
?	≤50	30	82.5±37.8	0.141
?	>50	24	101.9±47.0	?
病理类型		?	?	?
?	浸润性癌	42	95.7±45.2	0.150
?	非浸润性癌	12	75.3±32.2	?
肿瘤分期		?	?	?
?	Ⅰ/Ⅱ	41	86.7±37.8	0.022
?	Ⅲ	13	101.0±53.1	?
淋巴结转移		?	?	?
?	阴性	28	79.1±31.1	0.035
?	阳性	26	104.2±50.7	?
雌激素受体		?	?	?
?	阳性	29	87.8±41.8	0.574
?	阴性	25	95.0±45.3	?
孕激素受体		?	?	?
?	阳性	26	93.1±41.0	0.751
?	阴性	28	89.3±45.9	?
HER2		?	?	?
?	阳性	19	102.9±42.8	0.146
?	阴性	35	84.8±45.9	?

[1]	Xu Zhang, Jianping Xu, Dongming Su, Caifen Wang, Dali Wang, Wenzhi Zhang. Contrast-enhanced ultrasound features of male breast masses [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 854-859.
[2]	Hua Shao, Ziyue Na, Hui Jing, Bo Li, Qiucheng Wang, Wen Cheng. Value of preoperative percutaneous contrast-enhanced ultrasound in diagnosis of axillary sentinel lymph node metastasis and burden in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 849-853.
[3]	Meiwu Zhang, Shuyi Lyu, Xiaoxiang Fan, Luhui Zhuang, Yuqin Qiu, Baisong Zhang, Yan Zhang. Clinical value of ultrasound-guided aspiration combined with hypertonic glucose flushing in treatment of postoperative subcutaneous effusion in patients with breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(03): 327-331.
[4]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[5]	bing Feng, Qiuguo Zou, Zhenbo Liang, Yanming Lu, Yi Zeng, Shumiao Wu. Clinical study of ultrasonic signs and molecular biological indicators of senile non-specific invasive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 48-51.
[6]	Jia Wang, Baoliang Guo, Shan Wang, Dianlong Zhang, Mijia Wang, Tianyang Zhou, Jianguo Zhang, Feng Jin. Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 250-254.
[7]	Yating Wu, Shenghang Zhang, Shuiliang Wang. Research progress in the role of dysregulated RNA m⁶A modification in breast cancer metastasis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 45-52.
[8]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[9]	Fei Liu, Yingxin Wang, Xing Ma, Ling Xin, Yuanjia Cheng, Qian Liu, Yue Wang, Junjun Zhang. Different conductive media for intracavitary electrocardiogram-guided arm port implantation among breast cancer patients: a randomized controlled trial [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 760-764.
[10]	Qiyue Zhang, Xiaodong Wang. Progress in understanding of relationship between IL-8 and tumor immunity [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 605-613.
[11]	Fan Yang, Hong Zhang, Jiay Li, Ling Xin, Hongyu Xiang, Qian Liu, Yuanjia Cheng, Jingming Ye, Xuening Duan, Yinhua Liu, Ling Xu, Shuang Zhang. Characteristics of CK5/6 expression in early triple-negative breast cancer: correlation with prognosis and efficacy of neoadjuvant chemotherapy [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1081-1088.
[12]	Exian Mou, Hao Wang, Li Xia, Juan Li, Shiyan Zeng, Miao Yu, Junjie Li, Jia Xu, Purong Zhang, Man Lu, Hui Li, Shiwei Liu. Contrast-enhanced ultrasonography combined with blue dye for sentinel lymph node biopsy in neoadjuvant-treated HER2-positive or triple-negative breast cancer with initially biopsy-proven nodal metastasis [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1068-1074.
[13]	Junwei Cui, Yinhua Liu, Xiaoling Liu, Yibing Hu, Hui Hu. Efficacy and safety of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1062-1067.
[14]	Yilin Xu, Hong Lu, Xuejing Liu, Yujuan Hao, Ziling Yu, Ying Zhu. Value of imaging progress in precise axillary treatment of breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1054-1061.
[15]	Zeyu Cai, Huimin Lan, Ting Yu, Hui Luo. The study based on Ti₃C₂ loaded with doxorubicin and combined with photothermal therapy for inhibiting the proliferation of breast cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(02): 140-145.

Please choose a citation manager

Content to export